Database→ARA 290

Tier 2NeuropathyAnti-inflammatoryTissue RepairPREMIUM

ARA 290

Cibinetide (ARA 290 / Helix B Surface Peptide / HBSP)

Investigational. Not approved in any jurisdiction. US and EU Orphan Drug Designation for sarcoidosis-associated neuropathy. US FDA Fast Track designation. Successful end-of-Phase 2 FDA meeting completed. Not listed on WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

ARA 290 (cibinetide) is a synthetic 11-amino acid peptide derived from the tissue-protective helix-B domain of erythropoietin. It is the only peptide in this research series to demonstrate structural nerve regeneration (a 23% increase in GAP-43-positive fibers) in a double-blind RCT. It holds FDA Fast Track and Orphan Drug designations for sarcoidosis-associated neuropathy and has completed a successful end-of-Phase 2 FDA meeting.

🔒

Full Profile: Premium Members Only

The complete ARA 290 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use